3M Poaches Zimmer Biomet CEO Hanson to Lead Healthcare Spinoff
By Colin Kellaher
3M has named Bryan Hanson chief executive of its healthcare spinoff, plucking the executive from musculoskeletal company Zimmer Biomet Holdings.
3M on Tuesday said Hanson will join the St. Paul, Minn., industrial conglomerate on Sept. 1 as CEO of its healthcare business group, which is being spun off as an independent company.
Hanson has been president and CEO of Zimmer Biomet since late 2017 and chairman since 2021.
Zimmer on Tuesday said Ivan Tornos, its chief operating officer since March 2021, takes the helm as president and CEO effective immediately and is also joining the Warsaw, Ind., company's board.
Zimmer said Suketu Upadhyay, who joined as executive vice president and chief financial officer in 2019, is taking on oversight of the company's global operations and supply-chain functions, while its lead independent director, Christopher Begley, succeeds Hanson as chairman.
3M in July 2022 unveiled plans to spin off the healthcare business, which had $8.4 billion in sales in 2022, joining the ranks of conglomerates using such moves to distinguish business lines with the potential for better sales and profit growth.
3M on Tuesday said healthcare industry veteran Carrie Cox will serve as chairman of spinoff.
Write to Colin Kellaher at colin.kellaher@wsj.com
Corrections & Amplifications
This article was corrected at 8:56 a.m. ET because it incorrectly said the plan to spin off the healthcare business was unveiled in June. In July 2022, MMM unveiled plans to spin off the healthcare business.
(END) Dow Jones Newswires
August 22, 2023 09:00 ET (13:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations